Market Share of Global Pancreatic Cancer Therapeutics and Diagnostics Industry
The Pancreatic Cancer Therapeutics and Diagnostics market is highly competitive, with many key players dominating the market. The presence of major market players like Novartis AG, Pfizer Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Myriad Genetics Inc., and Viatris Inc. is intensifying the competition. The market players are adopting strategies, such as rising R&D investments, mergers, acquisitions, and product innovations, to sustain the increasing market rivalry. For instance, in January 2021, Myriad Genetics Inc. entered into a strategic partnership with Illumina Inc. for the latter to create a kit-based version of the myChoice companion diagnostic (CDx) test for international markets, which can be used to detect pancreatic cancer.
Pancreatic Cancer Therapeutics & Diagnostics Market Leaders
Myriad Genetics, Inc.
Pfizer, Inc
Novartis AG
Bristol-Myers Squibb Company
AstraZeneca plc
*Disclaimer: Major Players sorted in no particular order
